Artrya Limited has received regulatory approval for its Salix Coronary Anatomy (SCA) product in the United Kingdom. The European Notified Body (BSI) has notified Artrya that the assessment for UKCA Class 2 Certification has been completed and they will recommend certification of the Salix V2.0 Software for marketing into the United Kingdom. The BSI assessment scope includes UKCA certification in accordance with the UK Medical Devices Regulations 2002 and Artrya's Salix AI Coronary Software met or exceeded all regulatory requirements.

Once the UKCA certificate has been issued by BSI, Artrya is able to market the Salix software in the UK. Artrya already has a four-year contract in place to supply 1,250 National Health Service Trust Hospitals throughout the UK with the SCA product. The company is now able to approach these hospitals to finalise arrangements for the product roll out.

Other business development activities in the UK are well advanced for use of the SCA product within clinical practices outside of the National Health Service network.